Abstract
Recent developments in the epidemiology, diagnosis and therapy of malignant melanoma are reviewed, with particular attention paid to established standards of care. When melanoma metastases are inoperable, they respond poorly to the various chemotherapy strategies, so that additional improvements are critically needed. Cytotoxic T-lymphocyte antigen-4 antibodies, multikinase inhibitors, anti-apoptotic strategies and several other approaches are in progress in Phase III trials both as monotherapy as well as in combination with standard chemotherapy.
| Translated title of the contribution | Recent aspects of medical care of malignant melanoma |
|---|---|
| Original language | German |
| Journal | JDDG - Journal of the German Society of Dermatology |
| Volume | 6 |
| Issue number | 10 |
| Pages (from-to) | 868-880 |
| Number of pages | 13 |
| ISSN | 1610-0379 |
| DOIs | |
| Publication status | Published - 10.2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Recent aspects of medical care of malignant melanoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver